D. Cherney

Chronic kidney disease in type 1 diabetes: translation of novel type 2 diabetes therapeutics to individuals with type 1 diabetes.

P. Groop, H. Heerspink, Christine P. Limonte, 2023, Diabetologia.

PERL in Diabetes Study : A Randomized Double-Blinded Trial of Allopurinol d Rationale , Design , and Baseline Data

J. McGill, I. D. de Boer, A. Galecki, 2019 .

Use of sodium–glucose cotransporter-2 inhibitors and risk of acute kidney injury in older adults with diabetes: a population-based cohort study

A. Garg, N. Tangri, E. McArthur, 2020, Canadian Medical Association Journal.

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes.

J. McGill, I. D. de Boer, A. Galecki, 2020, The New England journal of medicine.

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

J. McMurray, T. Greene, D. Wheeler, 2020, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases.

L. Tokgözoğlu, Y. Handelsman, P. Jellinger, 2024, Metabolism: clinical and experimental.